Clinical Trials in Belagavi, Karnataka

9 recruiting

Showing 18 of 8 trials

Recruiting
Phase 3

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Relapsed or Refractory Multiple Myeloma
Celgene810 enrolled266 locationsNCT05519085
Recruiting
Phase 3

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

Heart Failure
Novo Nordisk A/S5,600 enrolled1117 locationsNCT05636176
Recruiting
Phase 3

A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

Heart FailureSystemic Inflammation
Novo Nordisk A/S680 enrolled239 locationsNCT06200207
Recruiting
Phase 3

A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

Chronic Kidney DiseaseSecondary Hyperparathyroidism
Amgen56 enrolled43 locationsNCT03633708
Recruiting
Phase 3

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Biliary Tract Cancer
Jazz Pharmaceuticals286 enrolled183 locationsNCT06282575
Recruiting
Phase 4

A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

Non-metastatic Castration-resistant Prostate Cancer
Bayer50 enrolled25 locationsNCT05348876
Recruiting
Phase 3

C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV

Hepatitis CHepatitis C, ChronicHepatitis C Virus Infection+1 more
Atea Pharmaceuticals, Inc.880 enrolled89 locationsNCT07037277
Recruiting
Phase 1

A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)

Relapsed Advanced Lymphomas
Aurigene Discovery Technologies Limited40 enrolled20 locationsNCT05984147